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Methamphetamine use among adolescents is a significant social and public
health concern. Despite increased awareness of methamphetamine use among
younger people, relatively little research has examined the effects of adolescent
methamphetamine use compared to adult use. Thus, much remains to be learned about
how methamphetamine alters adolescent brain function and behavior. In this article
we review recent trends in adolescent methamphetamine use and data examining the
effects of adolescentmethamphetamine use on the dopaminergic system and behavior in
humans and animal models. Future research is warranted to expand our understanding
of the effects of adolescent methamphetamine exposure and how those effects differ
from those seen in adults.
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Introduction
Methamphetamine (MA) use and abuse is a major public health concern in the United States
(NIDA, 2006, 2013; DASIS, 2008). MA’s primary mechanism of action is on the brain dopamine
(DA) system, resulting in high abuse potential, neurotoxic effects on the DA system, and behavioral
and cognitive impairments in adults (Sulzer et al., 2005). Historically, MA was primarily used by
adults and was not commonly used by adolescents, but in more recent years the demographic
profile of MA use has widened to include adolescents (Rawson et al., 2007; Gonzales et al., 2010).
Epidemiological research suggests that compared to other drugs of abuse, adolescent MA use is
relatively low in the United States. The most contemporary data from the Monitoring the Future
Survey in 2013 shows past-year MA use among 8th and 10th graders at 1.0% and among 12th
graders at 0.9% (Johnston et al., 2013). These current rates of MA use among youth are lower
than the initial measurements obtained in 1999, suggesting overall decreases in adolescent MA
use (Johnston et al., 2013). Caution should be taken, however, when interpreting these national
trends. While indeed encouraging, other data suggest a more concerning situation. For example,
MA-related emergency department visits rose from 67,954 in 2007 to 102,961 in 2011 (DAWN,
2014), suggesting negative and severe consequences of MA among those using the drug. The
percentage of adolescents admitted to Los Angeles County adolescent drug treatment centers with
MA as their primary drug of abuse has increased since 2002 (8% in 2002 and 31% in 2005) (Gonzales
et al., 2008). Adolescent MA users show poorer treatment response and are less likely to remain
drug-free during treatment compared to non-MA using adolescents (Rawson et al., 2005). Thus,
while downward national trends in self-reported adolescent MA use are promising, adolescent MA
use remains an issue that warrants attention.
While much research has focused on the effects of adult MA use, relatively little research has
examined the effects of MA use in adolescents. As adolescence is a dynamic period of brain and
behavior development (Spear, 2000), it is important that we better understand the effects of MA
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exposure on the adolescent brain and how these effects may
differ from those seen in adults. This review will summarize the
literature examining the effects of adolescent MA use in humans
and animal models and briefly compare these results to those
found in adults.
The Effects of Adolescent MA Use
MA use during adolescence causes distinct effects from other
drugs of abuse. Adolescents in treatment for MA abuse have an
increased likelihood of a history of psychiatric treatment and
a family history of drug misuse (Miura et al., 2006). Similarly,
Rawson et al. (2005) found that adolescents in treatment for MA
abuse show increased rates of depression and suicide ideation
compared to adolescents in treatment for other drugs of abuse
(Rawson et al., 2005). Adolescent MA users are more likely
to have had previous treatments for drug abuse compared to
adolescents using other drugs of abuse (Gonzales et al., 2008).
Adolescent MA users are also more likely to be female, which
differs frommost other abused drugs (Rawson et al., 2005; Miura
et al., 2006; Gonzales et al., 2008). MA use during adolescence
is associated with increased rates of risky sexual behavior and
adolescent pregnancy, as well as behavioral problems such as
increased anti-social behaviors (Zapata et al., 2008; Embry et al.,
2009).
The MA-induced psychological and behavioral alterations in
adolescent users appear to persist even after the termination
of MA use, as abstinent adolescent MA users show increased
depression and anxiety scores and increased cortisol secretion
following a social stressor compared to non-MA users after
4–11 months of abstinence (King et al., 2010b). Abstinent
adolescent MA users also show executive function impairments
after 4–11 months of abstinence compared to non-MA using
adolescents (King et al., 2010a). The long-term effects of MA
in adolescent users parallel certain long-term effects observed
in abstinent adult MA users, who also show impairments in
executive functions (for a review, see Scott et al., 2007), increased
levels of depression, and increased anxiety (Zweben et al., 2004;
Salo et al., 2011; Li et al., 2013). However, the number of
studies on adolescent MA users is limited compared to those in
adults, and the time of abstinence in the adolescent studies is
relatively short (4–11 months), necessitating further research to
understand the potential severity and duration of the long-term
effects of adolescent MA use.
To the best of our knowledge, very few studies have assessed
the effects of MA on functional or anatomical brain measures
in adolescent users. Sung et al. (2013) examined brain levels
of N-acetylaspartate plus N-acetylaspartyl glutamate (tNAA)
and phosphocreatine plus creatine (PCr+Cr) ratios, which are
brain metabolite markers of neuronal viability and integrity,
in current adolescent MA users. The authors found that MA
users do not show significant changes in mid-frontal gray matter
tNAA/ PCr+Cr ratios (Sung et al., 2013). This differs from
abstinent adult MA users, who show significantly lower brain
tNAA levels (Nordahl et al., 2002). However, there is a significant
negative correlation between tNAA/PCr+Cr and the duration
of MA use in adolescent MA users (Sung et al., 2013). Lifetime
doses of MA in adolescent users are also positively correlated
with the size of the left putamen and novelty seeking behavior
(Churchwell et al., 2012). Taken together, these data suggest
that certain MA-induced brain changes in adolescent users may
be similar to those found in adults, but much more research
assessing other aspects of brain function in adolescent MA users
is required in order to delineate how MA alters the adolescent
brain.
Effects of Adolescent MA Use in Animal
Models
Few studies have assessed functional and structural brain
measures in adolescent MA users. Thus, preclinical research has
been crucial for our understanding of the effects of MA exposure
on the adolescent brain and how these effects may differ from
those in the adult brain. While it appears that some of the
cognitive, behavioral, and psychological effects of MA are similar
between adolescent and adult users, animal studies suggest that
the adolescent brain is partially protected against the neurotoxic
effect of MA on the DA system compared to the adult brain. For
example, adolescent male mice at 1 month of age exposed to a
high dose of MA (4× 10mg/kg) show 50% reductions in striatal
DA levels 72 h post exposure, whereas adult mice at 12 months
of age exposed to the same dose of MA show 80% reductions in
striatal DA levels (Miller et al., 2000). Adolescent rats exposed to
high doses ofMA (4×10mg/kg) on postnatal day (PND) 40 show
no changes in DA uptake, dopamine transporter (DAT) binding,
DAT activity, and tyrosine hydroxylase activity in the striatum
7 days after exposure, whereas these dopaminergic measures are
reduced following the same doses of MA in adult rats exposed
on PND 90 (Kokoshka et al., 2000; Riddle et al., 2002). Biweekly
injections of MA (7.5mg/kg) for 6 weeks starting in adolescence
on PND 40 attenuates MA-induced decreases in striatal vesicular
DA uptake in adulthood on PND 90 in rats (McFadden et al.,
2011). High doses of MA (4 × 10mg/kg) in adolescent rats
on PND 40 moderately reduce vesicular DA uptake 1 h post
exposure, whereas the effects of MA on vesicular DA uptake
in the adult rat on PND 90 are significantly more severe 1 h
post exposure (Truong et al., 2005). This dose of MA also does
not reduce striatal DA levels or vesicular DA uptake 1 week
after exposure in adolescent rats, whereas these measures are
reduced 1 week post-treatment in adult rats (Truong et al., 2005).
In contrast, Kokoshka et al. (2000) showed that reductions in
striatal DA uptake and DAT activity occur in both adolescent and
adult rats 1 h post MA exposure, suggesting that the immediate
effects of MA are similar amongst adolescents and adults, but
that these effects mitigate more rapidly in the adolescent brain
(Kokoshka et al., 2000). Interestingly, Kokoshka et al. (2000)
also showed that the effect of MA on the serotonin system, as
measured by reductions in tryptophan hydroxylase activity, are
present in both adolescent and adult rats at 1 h and 7 days post
MA exposure (Kokoshka et al., 2000). Similarly, MA exposure
increases cFos activity in a variety of brain regions to comparable
levels in both adolescent and adult mice (Zombeck et al., 2010).
These findings suggest that adolescent and adult MA exposure
causes indiscriminate impairments in serotonergic function and
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activation of various brain regions, in contrast to the apparent
age-specific effects exerted by MA on the DA system.
The mechanisms underlying the relative resistance to the
effects of MA on the DA system in the adolescent rodent brain
are not well understood. Importantly, the attenuated toxicity
of MA in adolescents vs. adults is not due to differences in
MA-induced hyperthermia, as both adolescent and adult rats
show comparable increases in body temperature following MA
exposure (Kokoshka et al., 2000; Truong et al., 2005). The relative
resistance in adolescence to the neurotoxic effects of MA on
the DA system may be due in part to developmental differences
in the DA system. Adolescent rodents show increased levels
of functionally active DAT and increased vesicular monoamine
transport of DA into vesicles compared to adult rats (Volz
et al., 2009). The DA D1 and D2 receptors show increased
expression in the striatum and nucleus accumbens until PND
40 in adolescence, when they begin to decrease as adulthood is
reached, which may reflect the pruning of excess dopaminergic
synapses during this developmental time period (Teicher et al.,
1995). Alternatively, pharmacokinetic factors may mediate the
age-dependent effects of MA in the rodent brain. Plasma and
striatal levels of MA are much higher in adult rats on PND
90 compared to adolescent rats on PND 40 1 h after MA
exposure (Kokoshka et al., 2000). In contrast, Zombeck et al.
(2009) found little to no difference in brain MA concentrations
between adolescent and adult mice up to 240min post MA
exposure, suggesting similar peak levels of MA and a similar
pharmacokinetic time course in both age groups (Zombeck et al.,
2009). These conflicting data demonstrate that more research is
needed to determine if pharmacokinetic differences mediate the
differential effects ofMA on the DA system in adolescent vs. adult
rodents.
The effects of MA on the hypothalamic pituitary-adrenal
(HPA) axis are of particular interest, as adolescent MA users
show increased rates of depression, suicide ideation, anxiety,
and enhanced cortisol release following a stressor compared
to controls (Rawson et al., 2005; King et al., 2010b). As MA-
induced alterations in the HPA axis and stress responsiveness
could have significant effects on other brain neurotransmitter
systems and behavior, it is important to model the potential MA-
induced changes in the HPA axis in adolescent animals. MA
exposure during early adolescence (4 × 7.5mg/kg on PND 30
and 31) decreases vasopressin-immunoreactive neurons in the
paraventricular nucleus of the hypothalamus later in adolescence
in male mice (Joca et al., 2014). Unpublished findings from our
lab also suggest that early adolescent MA exposure tends to
reduce serum corticosterone levels later in adolescence. Although
these findings did not reach statistical significance, further
research is required to characterize the effects of adolescent MA
exposure on HPA axis function.
Much research has examined the behavioral and cognitive
effects of MA in adult rodents. However, relatively few studies
have examined the behavioral and cognitive effects of MA
exposure in adolescent rodents. Joca et al. (2014) modeled the
increased rates of depression among human adolescent MA
users, showing that early adolescent MA exposure (4× 7.5mg/kg
on PND 30 and 31) increases depression-like behavior in the
Porsolt forced swim test in late adolescent male and female
mice, an effect that persisted into adulthood (Joca et al., 2014).
However, the authors did not examine the effects of adult MA
exposure in this study, rendering it difficult to compare this
behavioral effect of MA to an adult age group. Nonetheless,
these findings model the increases in depression rates and suicide
ideation found in adolescent human MA users (Rawson et al.,
2005). In order to model and better understand the effects of
human adolescent MA use, additional research is warranted to
assess the effects of adolescent MA exposure on depression and
anxiety behaviors and related brain circuits.
Other research examining the behavioral effects of MA
exposure in adolescent and adult rodents has shown that MA
can exert unique effects in adolescence. Adolescent mice (PND
30-35) show more moderate increases in locomotor activity up
to 60min (Zombeck et al., 2009) or up to 90min (Zombeck
et al., 2010) following an injection of MA (2mg/kg) compared
to adult mice (PND 69-74). Furthermore, 4mg/kg of MA results
in prolonged increases in locomotor activity for 100min post
injection in adult mice (PND 69-74), whereas the increased
locomotor activity in adolescent mice (PND 30-35) begins to
decline approximately 60min post-treatment (Zombeck et al.,
2010). Similarly, repeated exposure to 0.5mg/kg MA increases
locomotor activity in both adolescent and adult rats, but these
increases are more moderate in the adolescent rats (PND 34-38)
compared to the adults (PND 66-70) over 5 days of exposure
(Zakharova et al., 2009). In contrast to the mitigated effects
of MA on locomotor activity in adolescent vs. adult rodents,
adolescent rats aremore susceptible to the conditioned rewarding
effects of MA than adults. Adolescent rats express MA-induced
conditioned place preference (CPP) following just 3 days of
training, while adult rats require 5 days of training to develop
MA-induced CPP (Zakharova et al., 2009).
Minimal research has examined the effects of adolescent MA
exposure on cognitive function in animal models. Exposure to
MA from PND 41-50 during adolescence (6.5mg/kg/day) results
in spatial learning impairments in the Morris water maze and
sequential learning impairments in the Cincinnati water maze.
However, exposure to MA at younger ages prior to adolescence
(PND 21-30 and PND 31-40) and older ages in adulthood
(PND 51-60) does not impair performance on these cognitive
tests, suggesting enhanced vulnerability during adolescence to
the deleterious cognitive effects of MA (Vorhees et al., 2005).
Adolescent MA exposure (10ml/kg from PND 41-50) results in
attenuated visual discrimination and impaired reversal learning
later in adulthood in rats, and also increases the amount of MA
that adult rats will self-administer (Ye et al., 2014). Exposure to
MA during early adolescence (4 × 7.5mg/kg on PND 30 and
31) in mice, however, does not impair cognitive function in the
Morris water maze or the novel object recognition test later
in adolescence or in adulthood (Joca et al., 2014). Adolescent
mice also lack short-term memory impairments and alterations
in hippocampal plasticity following neurotoxic doses of MA
(24mg/kg/day for 14 days), but this MA exposure paradigm
does impair spatial memory and hippocampal plasticity after 21
days of abstinence from the drug, suggesting that MA-induced
impairments may only appear after a period of abstinence in
Frontiers in Neuroscience | www.frontiersin.org 3 April 2015 | Volume 9 | Article 151
Buck and Siegel Effects of adolescent methamphetamine exposure
adolescence (North et al., 2013). Conflicting data assessing the
cognitive effects of adolescent MA exposure in animal models
necessitate further exploration of this topic. However, the MA-
induced cognitive impairments found by Vorhees et al. (2005)
and Ye et al. (2014) indicate that at the preclinical level MA may
lead to long-term impairments in a variety of cognitive domains.
These findings should be further explored to assess the potential
for similar impairments in humans following adolescent MA
use.
When considering the limited number of studies on
adolescent MA exposure in animal models, it is interesting to
note that despite the relative resistance of the adolescent DA
system to the neurotoxic effects of MA, adolescent rodents
nevertheless showMA-induced behavioral and cognitive changes
and impairments that are concerning from a translational
perspective. It is unclear what MA-induced brain changes may
underlie the MA-induced behavioral and cognitive alterations
in adolescence. While Joca et al. (2014) and Kokoshka et al.
(2000) showed MA-induced impairments in the vasopressin
system in the paraventricular nucleus of the hypothalamus
and the tryptophan hydroxylase system, respectively, further
research is required to understand MA-induced brain changes
in adolescence and how these changes result in the behavioral
and cognitive impairments noted in the studies above. It is
also important to note the broad spectrum of dosages and
exposure paradigms utilized in studies examining the effects
of adolescent MA confound efforts to conclusively understand
the effects of adolescent MA exposure. Studies use chronic
or acute MA exposure paradigms, a variety of MA doses, as
well as diverse MA administration methods (inter-peritoneal,
intravenous, intra-cerebral injection, etc.). Furthermore,
distinctions must be made between self-administration models
and experimenter-administered models, as the behavioral,
cognitive, and neurochemical outcomes of each may differ
in adolescents. The broad range of experimental designs in
MA exposure studies makes it challenging to find consistent
results, and future research should replicate previous exposure
paradigms and emphasize more standardized exposure models to
enable more meaningful comparisons among studies examining
the effects of adolescent MA exposure.
Conclusion
In summary, the current literature suggests that adolescent MA
use results in increased risky sexual behaviors and psychiatric
problems in humans, some of which are modeled in preclinical
research. Animal studies indicate that adolescent MA exposure
impairs cognitive function and can increase MA use later in life,
giving cause for concern in terms of what we might expect to
see in human MA users who initiated use during adolescence.
However, the brain basis of these impairments is yet to be
determined. Interestingly, the brain DA system seems to be
relatively resistant to the effects of MA during adolescence
as compared to during adulthood. This may arise due to
developmental changes in the DA system during adolescence,
and further research is warranted to better understand these
mechanisms. Research examining the effects of adolescent MA
exospore in animal models is limited in scope compared to
the research examining the effects of adult MA exposure.
This necessitates further research that delineates the potentially
unique brain and behavioral changes elicited by MA exposure in
adolescence.
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